Transcatheter Heart Valve Replacement Market - Strategic Insights and Forecasts (2026-2031)

The Transcatheter Heart Valve Replacement market is forecast to reach a valuation of USD 10,491.8 million in 2031, growing significantly from USD 6,740.6 million in 2026. This represents a robust Compound Annual Growth Rate (CAGR) of 9.3% during the forecast period.

The market's rapid growth is driven by several key factors including the increasing preference for minimally invasive transcatheter procedures, ongoing technological innovations in valve design and delivery systems, and expanding regulatory approvals. Additionally, the rising global elderly population, increasing prevalence of cardiovascular disease, and expansion of healthcare systems supporting THVR adoption contribute significantly to this growth.

While the aortic valve remains the most frequently treated, the report highlights significant advancements in mitral and tricuspid valve replacement systems. These developments are crucial for addressing previously untreated patient groups and expanding treatment options beyond aortic applications, particularly through innovative transseptal approaches.

The report indicates that Medtronic is strengthening its role in the market, particularly in transcatheter aortic valve therapies. This is evidenced by the meaningful growth in their Structural Heart and Aortic segment revenue, which climbed from USD 883 million in FY 2024 to USD 944 million in FY 2025.

In the United States, Medicare reimbursements for TAVR procedures are vital and depend on the procedure being performed per FDA-approved indications within a multidisciplinary team approach. This policy provides continued coverage by linking reimbursements to outcomes data and registry participation, which further develops evidence supporting TAVR procedures.

Transcatheter therapies are now an option for patients across high, medium, and low surgical risk classifications, supported by strong scientific evidence for safety and efficacy. Regulatory approvals and indication expansions, including for asymptomatic severe aortic stenosis and redo procedures, are further broadening access to these minimally invasive treatments for a wider range of patients.